Granza Bio
Building programmable therapeutics for the immune system
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
- Website
- granzabio.com
- City
- San Francisco
- Country
- United States
- YC batch
- Winter 2024
- Team
- 8 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in San Francisco
Innovaccer$1.3bn
Indian digital healthcare company.
Thatch$1bn
Health benefits. Valued at $1bn (September 2026).
Chan Zuckerberg BiohubLab
Nonprofit research network building virtual cell models.
AthelasHiring
Extensible, Integrated Technology that Simplifies Health Systems
ClipboardHiring
Every shift, Covered.
Benchling
Unlocking the power of biotech with modern software for modern science
Claim this profile
Free and instant: prove you run granzabio.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Granza Bio across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Granza Bio's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
